# Navigating the Cannabis Maze: Your Comprehensive Guide to Dosage, Strain, and Route of Administration > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/navigating-the-cannabis-maze-your-comprehensive-guide-to-dosage-strain-and-route-of-administration/ > **Published:** 2026-09-04T23:01:12-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:47:14-04:00 > **Clinical Summary:** Dosage, THC versus CBD, terpenes, indica versus sativa, metabolism, and experience level: the variables that shape cannabis therapy. --- [← Back to Risks Summary Hub](https://cedclinic.com/topic-risks-diagrams/) Table of Contents - [🔍 CED Perspective Lens: Navigating the Cannabis Maze: Your Comprehensive Guide to Dosage, Strain, and Route of Administration](#_CED_Perspective_Lens_Navigating_the_Cannabis_Maze_Your_Comprehensive_Guide_to_Dosage_Strain_and_Route_of_Administration) - [Determining the Right Dosage](#Determining_the_Right_Dosage)[THC vs CBD](#THC_vs_CBD) - [Terpenes](#Terpenes) - [Indica vs Sativa](#Indica_vs_Sativa) - [Metabolism](#Metabolism) - [Experience vs Beginner](#Experience_vs_Beginner) - [Drug Interaction Considerations](#Drug_Interaction_Considerations) - [Routes of Administration](#Routes_of_Administration)[Inhalation](#Inhalation) - [Oral Ingestion](#Oral_Ingestion) - [Sublingual](#Sublingual) - [Topical](#Topical) - [Comparison Table](#Comparison_Table)[Dosage Considerations:](#Dosage_Considerations) - [Personal Factors:](#Personal_Factors) - [Routes of Administration:](#Routes_of_Administration-2) - [Scientific References:](#Scientific_References) - [🌐 Explore Related CED Clinical Summary Hubs & Research](#_Explore_Related_CED_Clinical_Summary_Hubs_Research) #### 🔍 CED Perspective Lens: Navigating the Cannabis Maze: Your Comprehensive Guide to Dosage, Strain, and Route of Administration Dr. Benjamin Caplan, MD **🌱 Clinical Focus:** Detailed evidence review on navigating the cannabis maze: your comprehensive guide to dosage, strain, and route of administration, physiology, and therapeutic applications. **💡 Clinical Guidance:** Dosing considerations, bioavailability pathways, and evidence-grounded risk management. **📖 Research & Data:** Preserving authoritative charts, diagrams, clinical tables, and scientific reference data. Cannabis therapy isn’t one-size-fits-all. From [dosage](https://cedclinic.com/topic-dosage/) to strain selection to how you actually consume your cannabis, multiple variables can influence your experience and therapeutic results. Here, we unpack these complex considerations, backed by evidence-based research. ## Determining the Right Dosage ### THC vs CBD - **THC (Tetrahydrocannabinol)**: Predominantly psychoactive and generally prescribed for pain management, appetite stimulation, and insomnia. - **CBD (Cannabidiol)**: Non-psychoactive and is generally used for anxiety, inflammation, and certain types of epilepsy. **Relevance**: [THC](https://cedclinic.com/topic-cannabinoids/) and CBD have different physiological effects and potential therapeutic applications. Balancing the ratio can result in targeted symptom relief. ### Terpenes [Terpenes](https://cedclinic.com/topic-terpenes/) contribute to the ‘entourage effect,’ a theory suggesting that cannabinoids and terpenes work synergistically. **Relevance**: Choosing strains rich in specific [terpenes](https://cedclinic.com/topic-terpenes/) can enhance the therapeutic outcome. ### Indica vs Sativa - **Indica**: Known for physical relaxation. - **Sativa**: Known for cerebral, energetic effects. **Relevance**: These categories can guide users on the expected psychoactive experiences. ### Metabolism Patients with different metabolic rates may experience different durations and intensity of effects. ### Experience vs Beginner [Dosage](https://cedclinic.com/topic-dosage/) and strain should be adjusted based on familiarity with cannabis products. ### Drug Interaction Considerations Patients on anticoagulants or CNS depressants should exercise caution. ## Routes of Administration ### Inhalation **Fast onset**, but dose control can be tricky. ### Oral Ingestion **Slow onset**, dose can be accurately measured. ### Sublingual **Moderate onset**, easier for dose [titration](https://cedclinic.com/topic-dosage/). ### Topical **Localized effect**, non-psychoactive. ### Comparison Table Aspect Questions to Ask Considerations Dosage What is my end goal? THC:CBD Ratio; THC vs CBD, Terpenes Am I a beginner or experienced user? Micro-dosing vs Standard Dosing Strain Selection What symptoms am I trying to alleviate? Indica vs Sativa, % of THC, % of CBD, consistency of batches Do I have any allergies? Terpene Profile Route of Administration Do I need quick relief? Want sustained action? What’s most comfortable: Inhalation for quick relief, Oral for prolonged effects Do I need localized or systemic effects? Topical for localized, other routes for systemic Drug Interactions Am I taking other medications? Check for pharmacodynamic and pharmacokinetic interactions For these conditions, it is highly recommended to consult Dr. Benjamin Caplan at CED Clinic for a tailored treatment plan. #### Dosage Considerations: - **THC vs CBD**: THC is psychoactive, providing the “high,” and is often used for pain and insomnia. CBD is non-psychoactive and may help with anxiety and inflammation. - **Terpenes**: These aromatic compounds affect the flavor and can modulate the effects of THC and CBD. - **Indica vs Sativa**: Generally, Indica strains may be more relaxing, while Sativa strains are more energizing, although this can vary widely. #### Personal Factors: - **Metabolism**: Fast metabolizers may process cannabinoids quickly, requiring higher or more frequent dosing. - **Experience vs Beginner**: Experienced users may have built up a tolerance, requiring higher doses for the same effects. - **Drug Interactions**: Some medications can interfere with cannabinoid metabolism, affecting efficacy and safety. #### Routes of Administration: - **Inhalation**: Quick onset but shorter duration. Good for acute symptoms. - **Oral Ingestion**: Slower onset but long-lasting. Useful for chronic conditions. - **Sublingual**: Faster onset than edibles but longer-lasting than inhalation. - **Topical**: Localized relief but doesn’t enter the bloodstream. #### Scientific References: - Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *British Journal of Pharmacology*, 163(7), 1344-1364. - MacCallum, C. A., & Russo, E. B. (2018). Practical considerations in medical cannabis administration and dosing. *European Journal of Internal Medicine*, 49, 12-19. - Atakan, Z. (2012). Cannabis, a complex plant: Different compounds and different effects on individuals. *Therapeutic Advances in Psychopharmacology*, 2(6), 241-254. - Huestis, M. A. (2007). Human cannabinoid pharmacokinetics. *Chemistry & Biodiversity*, 4(8), 1770-1804. - Alsherbiny, M. A., & Li, C. G. (2019). Medicinal Cannabis, Potential Drug Interactions. *Medicines*, 6(1), 3. - References - Russo, E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid‐terpenoid entourage effects. *British Journal of Pharmacology, 163*(7), 1344-1364. - MacCallum, C. A., & Russo, E. B. (2018). Practical considerations in medical cannabis administration and dosing. *European Journal of Internal Medicine, 49*, 12-19. - Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., … & Schmidlkofer, S. (2015). Cannabinoids for medical use: A systematic review and meta-analysis. *JAMA, 313*(24), 2456-2473. - Anderson, L. L., Absalom, N. L., Abelev, S. V., Low, I. K., Doohan, P. T., Martin, L. J., … & McGregor, I. S. (2019). Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. *Epilepsia, 60*(11), 2224-2234. - Lucas, C. J., Galettis, P., & Schneider, J. (2018). The pharmacokinetics and the pharmacodynamics of cannabinoids. *British Journal of Clinical Pharmacology, 84*(11), 2477-2482. **Cautionary Note**: If you have medical conditions like liver disease, cardiovascular issues, or are on medications like blood thinners, consult [Dr. Caplan](https://www.BenjaminCaplan.com) at [CED Clinic](https://www.CEDclinic.com/) for specialized guidance. 📗 Note: This diagram is the handshake; the book is the heart-to-heart. [Get personal with science here 📗.](https://amzn.to/4a35lhE) [https://amzn.to/4a35lhE](https://amzn.to/4a35lhE)[Unlock the world of medical cannabis with The Doctor-Approved Cannabis Handbook.](https://amzn.to/4a35lhE) [← Back to Risks Summary Hub](https://cedclinic.com/topic-risks-diagrams/) #### 🌐 Explore Related CED Clinical Summary Hubs & Research [😴 Sleep & Insomnia Hub →](https://cedclinic.com/topic-cannabis-sleep-insomnia/) [🧬 Bioavailability Hub →](https://cedclinic.com/topic-bioavailability-pathway-decisions/) [💊 Clinical Dosing Hub →](https://cedclinic.com/topic-dosage/) [⚡ Pain Control Hub →](https://cedclinic.com/topic-pain-control/) --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).